1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Beckley Psytech To Evaluate Psilocybin In A Rare Debilitating Headache

VC-Backed Biotech To Target SUNHA

 
• By John Davis

The effect of low-dose psilocybin, a compound found in mushrooms, on a rare debilitating condition, short-lasting unilateral neuralgiform headaches attacks, is to be evaluated by the 2019-founded UK biotech, Beckley Psytech.

mushrooms Psilocybe
Psilocybe mushrooms • Source: Alamy

The UK company Beckley Psytech is the latest biotech to raise investor funding to support the evaluation of psychedelic compounds, and in particular the serotonin 5HT2-alpha agonist, psilocybin, as potential therapeutics, a sector that has seen companies marshalling resources to develop their candidates, often with weighty financial backing. 

For example, the Berlin, Germany-based company atai Life Sciences BV  raised $258

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.